Delusional Parasitosis Mimicking Cutaneous Infestation in Elderly Patients
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
AMANTADIP\Dle: on Nemolebtic-II[WDUCED CATALEPSY UV the RAT
J. Fac. Plmnz. Istanbul lstanbul Ecz. Fak. Mec. 29, 1 (1993) 29, 1 (1993) THE EFFECT OF CYPROHEPT~~AWEb AMANTADIP\dlE: ON NEmOLEBTIC-II[WDUCED CATALEPSY UV THE RAT SUMMARY Catalepsy is not a unitary phenomenon. With respect to biochemical mechanisms and neurotransmitter sytems, the origin of this behavioural response varies according to different substances which cause catalepsy. For example, the catdeptogenic effect of ne- uroleptics has been related to the blockage of striatal doparnine receptors. Neurophysio- logical and biochemical data have shown that a mechanism caused by gama-aminobuty- ric acid and serotonin have been effective in the proper functioning of the dopaminergic nigrosbriatal tract. We have studied the effects of cyproheptadine, a serotonin antagonist, and of amantadin which is used in the treatment of Parkinson syndrome on the catalepsy indu- ced by trifluoperazine, a phenothiazin compound, and pimozid, a drug used as a neuro- leptic. It was observed that when rats were pretreated with cyproheptadine as well as amantadiie, the catalepsy induced by the above neuroleptic drugs was attenuated. The results of our study show that substances which have an effect on the seroto- nergic and dopaminergic systems also play a role on cases of catalepsy induced by the neuroleptic drugs mentioned above. (*) Faculty of Pharmacy, Depament of Pharmacology, University of Istanbul, 31152, Istanbul, Turkey Katalepsi bir tek nedene bagh OWortaya qllian bit durum degildir. Biyokimya- sal ve norotransmitter sistemler agsmdan bu davran~glnsebebi, katalepsi olughYan qe- gitli maddeler iqin fad&&. Omegin noroleptiklerin kataleptojenik etkisi striatal dopa- min reseptorlerinin blokaj~nabajjlanmqtx. Niirofizyolojik ve biyokimyasal veriler do- pamine jik nigro-striatal sistemin duzenli $&$masmda gma-aminobutirik asid ve sero- tonin'e bagh olan bir mekanizmmn etkili oldugunu gostermigtir. -
Secondary Ekbom Syndrome to Organic Disorder: Report of Three Cases
541 CASO CLÍNICO L Síndrome de Ekbom secundária a transtorno orgânico: relato de três casos * Secondary Ekbom Syndrome to organic disorder: report of three cases Cinthia Janine Meira Alves 1 Antônio Carlos Ceribelli Martelli 2 Leticia Fogagnolo 3 Priscila Wolf Nassif 4 Resumo: A Síndrome de Ekbom, também conhecida como delírio de parasitose ou acarofobia, é um esta- do fóbico obsessivo no qual o paciente pensa, imagina ou acredita que está infestado por parasitas na pele. Em estado alucinatório, retira fragmentos de pele, identificando-os como parasitas. Pode tratar-se de um quadro psiquiátrico primário ou secundário a outros transtornos orgânicos. Geralmente, esses pacientes demoram a procurar ajuda médica, e o dermatologista, quase sempre, é o primeiro profissional procurado. Descrevemos o caso de três pacientes dos quais apresentaram delírio de parasitose, associados a transtornos orgânicos. Palavras-chave: Delírio; Dermatologia; Prurido; Psiquiatria Abstract: The Ekbom syndrome, also known as delusion of parasitosis or acarophobia is an obsessive pho- bic state in which the patient thinks, imagines or believes that his or her skin is infested by parasites. In the hallucinatory state, he/she removes parts of the skin, identifying them as parasites. It can be primary or secondary to other organic or psychiatric diseases. Generally speaking these patients take a long time to seek for medical support and the dermatologist is almost always the first physician to see them. Here we describe three patients with delusional parasitosis associated with organic disorders. Keywords: Delirium; Dermatology; Pruritus; Psychiatry INTRODUÇÃO Descrita, inicialmente por Thiberge, em 1894, O início dos sintomas pode ser brusco ou lento com o termo acarofobia, a síndrome foi definida, em e com queixas de sensação de prurido, pinicamento, 1938, por Ekbom, que deu seu nome. -
Schizophrenia Care Guide
August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic -
Monosymptomatic Hypochondriacal Psychosis (Somatic Delusional Disorder): a Report of Two Cases
SCIENTIFIC LETTER | http://dx.doi.org/10.4314/ajpsy.v16i2.11 Afr J Psychiatry 2013;16:87-91 Monosymptomatic Hypochondriacal Psychosis (somatic delusional disorder): A report of two cases Historically, the term Monosymptomatic Hypochondriacal abusing any psychoactive substances and was said to be well Psychosis (MHP) was first used by Munro in 1978. 1 MHP is adjusted premorbidly. Based on history and examination, she classified as a somatic type of delusional disorder in DSM- IV 2 was managed as a case of paranoid schizophrenia (with and is defined as an erroneous conviction of bodily disease, olfactory reference syndrome) and was treated with abnormality or alteration. 3 It includes delusional beliefs about haloperidol 15mg daily to which she responded positively bodily sensations or functions; such as feeling malodorous, after one week. As of when she was seen last in the out-patient being infected by parasites, having dysmorphic features, or clinic, she remained stable on maintenance dose of that a certain organ is no longer functioning. 4 MHP has been haloperidol 5mg nocte. divided into 4 main categories: Delusions of infestation Mr B was a 45 year old married, Christian saw-miller who (including parasitosis); delusions of dysmorphophobia, such presented with a year and a half history of the feeling that as of misshapenness, personal ugliness, or exaggerated size insects were crawling all over his body, a mucus substance of body parts (this seems closest to that of body dysmorphic entering his eyes and a three month history of inadequate disorder); delusions of foul body odours or halitosis or sleep. The insects were of different sizes and shapes (cubiodal delusional bromosis (also known as olfactory reference and cylindrical). -
Delusional Parasitosis in Dementia With
Ochiai et al. Ann Gen Psychiatry (2019) 18:29 https://doi.org/10.1186/s12991-019-0253-3 Annals of General Psychiatry CASE REPORT Open Access Delusional parasitosis in dementia with Lewy bodies: a case report Sho Ochiai1, Hiroko Sugawara1*, Yusuke Kajio2, Hibiki Tanaka1, Tomohisa Ishikawa1, Ryuji Fukuhara1, Tadashi Jono1,3 and Mamoru Hashimoto4 Abstract Background: Dementia with Lewy bodies (DLB) is characterized by fuctuating cognitive impairments, recurrent visual hallucinations, the motor symptoms of parkinsonism and REM sleep behavior disorder. Various neuropsychiatric symptoms including hallucination and delusions occur frequently; however, delusional parasitosis is rare in DLB. Here, we report a case of DLB patient with delusional parasitosis. Case presentation: The patient was an 89-year-old woman. At the age of 88, she began to complain her oral cen- esthopathy, and developed cognitive decline, delusional parasitosis and parkinsonism. As a result of examination, she was diagnosed as DLB and treated with combination of donepezil 5 mg/day and aripiprazole 1.5 mg/day, and her complaint was disappeared. Conclusions: Further studies are needed to investigate the association between delusional parasitosis and underly- ing pathophysiology of DLB, and the utility of antipsychotics for delusional parasitosis in DLB has to be examined through more cases. Keywords: DLB, Delusional parasitosis, Aripiprazole, Donepezil Background Delusional parasitosis, which is characterized by a Dementia with Lewy bodies (DLB) is recognized as the fxed and persistent belief of having a pathogenic infec- second common type of progressive neurodegenera- tion despite objective evidence to the contrary, is more tive dementia in elderly people following Alzheimer’s common in dermatology rather than psychiatry [7]. -
Diagnosis and Management of Delusional Parasitosis
Diagnosis and management of delusional parasitosis Elliott H. Campbell, BSc,a Dirk M. Elston, MD,b James D. Hawthorne, MD,c and David R. Beckert, MDd Lexington, Kentucky, and Charleston, South Carolina Delusional parasitosis is a monosymptomatic hypochondriacal state that causes great suffering for the patient and great suffering for those around them. Dermatologists are experts in the diagnosis of cutaneous disease and frequently encounter such patients. This review provides an overview of the diagnosis and management of delusional parasitosis and the differential diagnosis. ( J Am Acad Dermatol 2019;80:1428-34.) Key words: chronic tactile hallucinosis; delusional parasitosis; delusions of parasitosis; delusory parasitosis; Ekbom syndrome; psychogenic parasitosis. elusional parasitosis (DP), also commonly parasitosis, mood episodes have been brief relative D referred to as delusions of parasitosis, to the duration of the delusional period(s), and delusional infestation, or Ekbom syndrome, where the disturbance is not attributable to medical is a monosymptomatic hypochondriacal psychosis in conditions, substances, or another disorder.4 which affected individuals have a fixed, false belief We summarize the current literature regarding that they are infested with living organisms. The epidemiology, diagnosis, and management in this German term Dermatozoenwahn (parasitosis) was review. Evidence-based recommendations for phar- originally cited in 1938 by Karl Axel Ekbom to macologic management and side effect profiles of describe this disorder. The name Ekbom syndrome the available agents are discussed in the context of was later used to describe this disorder; however, this the authors’ experience. eponym is ambiguous because it can also be used to refer to restless leg syndrome.1 Morgellons disease is METHODS a condition in which a patient perceives fibers or The PubMed database was queried for relevant threads emerging from or attached to the skin. -
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209 -
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
pharmaceuticals Review Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma Rita Rebelo 1,2,† ,Bárbara Polónia 1,2,†,Lúcio Lara Santos 3,4, M. Helena Vasconcelos 1,2,5,* and Cristina P. R. Xavier 1,2,5,* 1 Cancer Drug Resistance Group, IPATIMUP—Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal; [email protected] (R.R.); [email protected] (B.P.) 2 i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal 3 Experimental Pathology and Therapeutics Group, IPO—Instituto Português de Oncologia, 4200-072 Porto, Portugal; [email protected] 4 ICBAS—Biomedical Sciences Institute Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal 5 Department of Biological Sciences, FFUP—Faculty of Pharmacy of the University of Porto, 4200-135 Porto, Portugal * Correspondence: [email protected] (M.H.V.); [email protected] (C.P.R.X.) † These authors equally contributed to this work. Abstract: Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a five-year survival rate of around 5%. Treatment of PDAC is still a major challenge, with cytotoxic chemotherapy remaining the basis of systemic therapy. However, no major advances have been made recently, and therapeutic options are limited and highly toxic. Thus, novel therapeutic options are urgently needed. Drug repurposing is a strategy for the development of novel treatments using approved or investigational drugs outside the scope of the original clinical indication. -
Ekbom Syndrome: a Delusional Condition of “Bugs in the Skin”
Curr Psychiatry Rep DOI 10.1007/s11920-011-0188-0 Ekbom Syndrome: A Delusional Condition of “Bugs in the Skin” Nancy C. Hinkle # Springer Science+Business Media, LLC (outside the USA) 2011 Abstract Entomologists estimate that more than 100,000 included dermatophobia, delusions of infestation, and Americans suffer from “invisible bug” infestations, a parasitophobic neurodermatitis [2••]. Despite initial publi- condition known clinically as Ekbom syndrome (ES), cations referring to the condition as acarophobia (fear of although the psychiatric literature dubs the condition “rare.” mites), ES is not a phobia, as the individual is not afraid of This illustrates the reluctance of ES patients to seek mental insects but rather convinced that they are infesting his or health care, as they are convinced that their problem is her body [3, 4]. This paper deals with primary ES, not the bugs. In addition to suffering from the delusion that bugs form secondary to underlying psychological or physiologic are attacking their bodies, ES patients also experience conditions such as drug reaction or polypharmacy [5–8]. visual and tactile hallucinations that they see and feel the While Morgellons (“the fiber disease”) is likely a compo- bugs. ES patients exhibit a consistent complex of attributes nent on the same delusional spectrum, because it does not and behaviors that can adversely affect their lives. have entomologic connotations, it is not included in this discussion of ES [9, 10]. Keywords Parasitization . Parasitosis . Dermatozoenwahn . Valuable reviews of ES include those by Ekbom [1](1938), Invisible bugs . Ekbom syndrome . Bird mites . Infestation . Lyell [11] (1983), Trabert [12] (1995), and Bak et al. -
CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack -
A Case of an RLS Mimic Treated with an Antipsychotic
Diso ep rde le rs S f & o T l h a e n r r a u p Hawa, J Sleep Disord Ther 2015, 4:3 o y Journal of Sleep Disorders & Therapy J DOI: 10.4172/2167-0277.1000198 ISSN: 2167-0277 Case Report Open Access A Case of an RLS Mimic Treated with an Antipsychotic Raed Hawa* University Health Network, Toronto Western Hospital, 399 Bathurst St, Main Pavilion 7th Floor, Rm#401, Toronto, Ontario M5T2S8, Canada *Corresponding author: Raed Hawa, University Health Network, Toronto Western Hospital, 399 Bathurst St, Main Pavilion 7th Floor, Rm#401, Toronto, Ontario M5T2S8, Canada, Tel: 416 603-5847; E-mail: [email protected] Received date: Mar 25, 2015, Accepted date: May 04, 2015, Published date: May 12, 2015 Copyright: © 2015 Hawa R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract This case reports on a restless leg syndrome mimic that has responded to antipsychotic medication. Keywords: Sleep medicine; Restless leg syndrome; Delusional buttocks when she sat down on the toilet seat. She definitely attributed parasitosis this incident to her symptoms as she was not able to sleep that night because of the “pinching sensation”. Since that time, she has become Introduction convinced that “something” has entered her body and resulted in the RLS symptoms. We report the case of a restless leg syndrome mimic that has responded to an antipsychotic medication. She was referred to an infectious disease specialist who confirmed the diagnosis as delusional parasitosis, based on her clinical presentation and lack of any evidence of a skin infestation. -
A Review of Delusions of Parasitosis, Part 1: Presentation and Diagnosis
CONTINUING MEDICAL EDUCATION A Review of Delusions of Parasitosis, Part 1: Presentation and Diagnosis Rachel Bak, MD; Phani Tumu, MD; Christina Hui, MD; David Kay, BA; Julie Burnett; David Peng, MD GOAL To understand delusions of parasitosis (DOP) to better manage patients with the condition OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Identify criteria for diagnosing DOP. 2. Describe features associated with DOP. 3. Discuss possible causes of DOP. CME Test on page 136. This article has been peer reviewed and approved Einstein College of Medicine is accredited by by Michael Fisher, MD, Professor of Medicine, the ACCME to provide continuing medical edu- Albert Einstein College of Medicine. Review date: cation for physicians. July 2008. Albert Einstein College of Medicine designates This activity has been planned and imple- this educational activity for a maximum of 1 AMA mented in accordance with the Essential Areas PRA Category 1 CreditTM. Physicians should only and Policies of the Accreditation Council for claim credit commensurate with the extent of their Continuing Medical Education through the participation in the activity. joint sponsorship of Albert Einstein College of This activity has been planned and produced in Medicine and Quadrant HealthCom, Inc. Albert accordance with ACCME Essentials. Drs. Bak, Tumu, Hui, and Peng; Mr. Kay; and Ms. Burnett report no conflict of interest. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. Delusions of parasitosis (DOP), a psychiatric and treatment with psychotropic medications. We disorder in which patients erroneously insist discuss the classification, epidemiology, clinical that they are infested with parasites, remains a presentation, etiology, associated features, and fascinating entity with elusive origins.